Advertisement

Risk factors for end-stage liver disease among HIV and hepatitis C virus co-infected patients in the Spanish VACH Cohort

  • R Teira
  • P Geijo
  • J Cosín
  • A Muñoz-Sanz
  • P Viciana
  • I Suarez-Lozano
  • J López-Aldeguer
  • E Pedrol
  • F Vidal
  • T Sanchez
  • F Lozano
  • A Terron
  • A Vergara
  • MJ Galindo
  • P Domingo
  • E Ribera
  • B Roca
  • ML Garcia-Alcalde
  • M Garrido
  • P Muñoz-Sanchez
Open Access
Poster presentation
  • 646 Downloads

Keywords

Portal Hypertension Chronic Liver Disease Hepatic Encephalopathy Spontaneous Bacterial Peritonitis Hepatorenal Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Background

There is increasing evidence supporting the hypothesis of a beneficial effect of highly active antiretroviral therapy (HAART) on the evolution and outcome of chronic liver disease (CLD) caused by hepatitis C virus (HCV) in HIV co-infected patients. The relative merit of different drugs or drug classes is, however, less well studied.

Methods

We performed a cross-sectional study on the VACH Cohort, a multicenter cohort of HIV-infected individuals in Spain, to ascertain the possible associations between exposure to protease inhibitors (PI) or to non-nucleoside analogues (NAN), and the outcome of HCV CLD. We selected HCV co-infected patients who had ever initiated HAART and who had at least one follow-up visit [treatment evaluable (TE)]. We defined our main "exposure" variable as the total time of treatment with any of, either, PI's or NAN's. We evaluated "outcome" as the occurrence of end stage CLD (ESLD), defined as any of: ascites, oesophageal varices, hepatic encephalopathy, hepatorenal syndrome, portal hypertension, hepatocellular carcinoma, or related diagnoses (i.e. upper gastrointestinal bleeding, spontaneous bacterial peritonitis).

Summary of results

Out of 15,183 patients in the VACH database, 6,004 were TE, of whom 2,669 (44,4%) were HCV co-infected; 128 patients (4.4%) developed an ESLD. Table 1 shows some important features of this sub-cohort, according to study group. The following factors (marked with * in Table 1) were associated with ESLD in the univariate analyses: being HBsAg-positive, nadir of CD4+ cell count, age and prior diagnosis of AIDS. Exposure to either PI's or NAN's was not. In a regression model, only HBsAg, age and nadir CD4+ cell count remained associated with ESLD. In a sensitivity analysis, Kaplan-Meier curves of time from initiation of HAART to diagnosis of ESLD, restricted to patients only exposed to one class of drugs, showed no differences between PI's and NAN's.

Table 1

 

female

prior AIDS*

ever IVDU

HBsAg+*

mean age*

1st CD4 cell count

log10 last viral load

nadir CD4 count*

ESLD

17.4%

43.7%

84.1%

12.5%

36.7

303.3

2.50

128.7

Other

20.2%

34.2%

82.2%

5.3%

34.6

311.1

2.45

170.6

Conclusion

In conclusion, we found no evidence to support the hypothesis of a different effect of PI's and NAN's on the occurrence of ESLD among HIV and HCV co-infected individuals. Hepatitis B co-infection, more profound immunosupression and older age were associated with this outcome.

Copyright information

© Teira et al; licensee BioMed Central Ltd. 2008

This article is published under license to BioMed Central Ltd.

Authors and Affiliations

  • R Teira
    • 1
  • P Geijo
    • 2
  • J Cosín
    • 3
  • A Muñoz-Sanz
    • 4
  • P Viciana
    • 5
  • I Suarez-Lozano
    • 6
  • J López-Aldeguer
    • 7
  • E Pedrol
    • 8
  • F Vidal
    • 9
  • T Sanchez
    • 10
  • F Lozano
    • 11
  • A Terron
    • 12
  • A Vergara
    • 13
  • MJ Galindo
    • 14
  • P Domingo
    • 15
  • E Ribera
    • 16
  • B Roca
    • 17
  • ML Garcia-Alcalde
    • 18
  • M Garrido
    • 19
  • P Muñoz-Sanchez
    • 20
  1. 1.Hospital de SierrallanaTorrelavegaSpain
  2. 2.Hospital Virgen de la LuzCuencaSpain
  3. 3.Hospital Gregorio MarañonMadridSpain
  4. 4.Hospital Infanta CristinaBadajozSpain
  5. 5.Hospital Virgen del RocíoSevillaSpain
  6. 6.Hospital Infanta ElenaHuelvaSpain
  7. 7.Hospital La FeValenciaSpain
  8. 8.Hospital GeneralGranollersSpain
  9. 9.Hospital Joan XXIIITarragonaSpain
  10. 10.Hospital Virgen del RosellCartagenaSpain
  11. 11.Hospital de ValmeSevillaSpain
  12. 12.Hospital SASJerezSpain
  13. 13.Hospital ClinicoPuerto RealSpain
  14. 14.Hospital ClinicoValenciaSpain
  15. 15.Hospital Santa Creu i Sant PauBarcelonaSpain
  16. 16.Hospital Vall d'HebronBarcelonaSpain
  17. 17.Hospital GeneralCastellonSpain
  18. 18.Hospital de CabueñesGijonSpain
  19. 19.VACH Data ManagementCartayaSpain
  20. 20.Hospital de BasurtoBilbaoSpain

Personalised recommendations